A CEA blood test measures carcinoembryonic antigen to help monitor colorectal cancer treatment and detect recurrence early; it can also assist clinicians in assessing other cancers (e.g., pancreatic, gastric, lung). By flagging rising levels sooner, it helps catch recurrence or progression early so treatment can be adjusted to reduce the risk of advanced disease and complications.

A CEA (carcinoembryonic antigen) blood test measures tumor-marker levels to help monitor colorectal (and some other) cancers, assess treatment response, and detect recurrence. Early detection of rising CEA can prompt timely follow-up and treatment, helping reduce the risk of advanced cancer progression and related complications.

A blood calcitonin test screens for elevated calcitonin from thyroid C‑cells to detect medullary thyroid carcinoma, C‑cell hyperplasia, and to monitor for recurrence after treatment. Early detection helps identify malignant thyroid nodules sooner so treatment can begin before the cancer spreads.

A Calcitonin blood test screens for abnormal thyroid C‑cell activity to help detect medullary thyroid carcinoma, C‑cell hyperplasia and some neuroendocrine tumours early. Early detection and monitoring allow timely treatment and reduce the risk of advanced thyroid cancer and related complications.

Identifies inherited RET gene mutations that raise risk for medullary thyroid carcinoma and MEN2-related endocrine tumors, enabling targeted surveillance and family testing. Knowing your RET status supports timely interventions (including preventive surgery or earlier treatment) that can greatly reduce the chance of advanced thyroid cancer and related complications.

Detects the BRAF V600E mutation — a driver in cancers such as melanoma, colorectal, papillary thyroid and certain leukemias — enabling clinicians to choose effective targeted therapies and avoid ineffective treatments or delays that can worsen outcomes.

Detect elevated calcitonin — an early marker of medullary thyroid cancer and C‑cell disorders — so you can find thyroid cancer or related neuroendocrine problems sooner and act before they progress. Ideal for people with thyroid nodules, family history, or for monitoring after thyroid cancer treatment.

This RET mutation test identifies inherited RET gene changes that signal elevated risk for medullary thyroid carcinoma and MEN2 syndromes. Early detection enables targeted surveillance or preventive treatment to help avoid advanced thyroid cancer, pheochromocytoma, and related life‑threatening complications.

The TG (thyroglobulin) antibody test detects antibodies against thyroglobulin to identify autoimmune thyroid disease and to ensure accurate thyroglobulin monitoring in thyroid cancer follow‑up. Early detection helps prevent untreated hypothyroidism, goiter and related complications (including impacts on fertility and pregnancy) by guiding timely treatment.

Detects thyroid peroxidase (TPO) antibodies to identify autoimmune thyroid disease (most commonly Hashimoto’s, sometimes Graves’); early detection enables timely treatment and monitoring to reduce the risk of developing hypothyroidism and related issues like fatigue, weight changes, fertility problems, and pregnancy complications.

This AFP (alpha‑fetoprotein) test screens in pregnancy for neural tube defects and certain chromosomal conditions and serves in adults as a marker to detect or monitor liver and germ‑cell cancers. Early detection enables timely follow‑up and treatment, helping reduce the risk of serious complications.

The AFP (alpha‑fetoprotein) test measures protein levels in maternal or patient blood to screen pregnancies for neural tube and abdominal wall defects and to help detect or monitor liver cancer and certain germ‑cell tumors. Early detection prompts follow‑up care and treatment, reducing risk of complications and improving outcomes.

A Beta-hCG test detects and measures pregnancy hormone levels to confirm pregnancy and monitor its early progress. Early results can help identify risks such as ectopic pregnancy, miscarriage, or trophoblastic disease so you can get prompt care and reduce the chance of serious complications.

Detects and measures pregnancy hormone (beta‑hCG) to confirm early pregnancy and monitor its progress quickly and accurately. Early detection and trending can reveal non‑viable pregnancies, ectopic or molar pregnancies, and abnormal developments so you can seek timely medical care.

An LDH (lactate dehydrogenase) test measures enzyme levels to detect tissue damage and cellular stress—helping identify early signs of heart attack, liver disease, hemolytic anemia, muscle injury, and some cancers. Catching abnormalities sooner lets you get prompt treatment and avoid more serious complications.

Detects the AR‑V7 androgen‑receptor splice variant in circulating tumor cells to predict likely resistance to AR‑targeted therapies (e.g., enzalutamide, abiraterone). Knowing your AR‑V7 status can help you avoid ineffective hormone treatments and their side effects, enabling faster transition to more appropriate therapy and reducing risk of disease progression.

This BRCA1 gene test screens for inherited variants that substantially raise lifetime risk of breast and ovarian cancer (and can also affect prostate, pancreatic, and male breast cancer risk). Knowing your BRCA1 status can help you and your healthcare provider begin earlier surveillance, risk‑reducing strategies, or targeted treatments that may lower your chances of advanced cancer.

A BRCA2 gene test detects inherited variants that substantially raise lifetime risk of breast and ovarian cancer (and also increase risks of pancreatic, male breast, and certain prostate cancers). Knowing your BRCA2 status lets you pursue enhanced screening and targeted risk‑reduction options (surveillance, preventive treatments or surgery) to detect cancer earlier or lower your chance of advanced disease.

This free PSA test screens prostate health by measuring PSA levels and the free/total PSA ratio to detect early signs of prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis. Early detection enables timely follow-up and treatment to reduce the risk of advanced disease and more invasive interventions.

Oncotype DX is a genomic assay that analyzes tumor gene expression—primarily in early‑stage breast cancer (including DCIS)—to predict recurrence risk and the likely benefit of chemotherapy. By clarifying recurrence risk and chemo benefit, it helps patients and clinicians personalize care and avoid unnecessary chemotherapy and its side effects.

Check your prolactin to detect hormonal imbalances that can cause infertility, irregular periods, unexpected milk production or low libido; identifying abnormal levels early can uncover treatable pituitary disorders (like prolactinoma) and help prevent long-term complications such as infertility and bone loss.

Check your prolactin to quickly detect hormone imbalances that can cause menstrual problems, infertility, low libido, unexpected milk production (galactorrhea) or pituitary disorders. Early detection helps prompt treatment and can prevent ongoing fertility issues, bone loss from hormonal disruption, or growth of pituitary tumors.

An AMH test measures your ovarian reserve to give a clear snapshot of your current fertility potential. Knowing your AMH can help you avoid surprises by identifying diminished ovarian reserve, early menopause risk, or signs of PCOS so you can pursue fertility preservation or targeted treatment sooner.

A CA‑125 blood test measures the level of the CA‑125 protein, a tumor marker most commonly used to help detect and monitor ovarian cancer. Identifying elevated or rising CA‑125 levels can prompt timely follow-up and treatment, potentially helping avoid delayed diagnosis or progression to more advanced disease.

The HE4 test measures levels of the HE4 protein to help detect and monitor epithelial ovarian cancer and to assess whether a pelvic mass is more likely benign or malignant. Used alongside CA‑125 and risk algorithms, it may help catch ovarian cancer earlier or spot recurrence sooner, enabling timelier treatment and potentially reducing the chance of advanced‑stage disease.

The Inhibin B test measures the reproductive hormone inhibin B to evaluate ovarian reserve in women and spermatogenic/testicular function in men. Early identification of low inhibin B or hormonal imbalance can prompt timely fertility treatment and investigation of testicular or ovarian dysfunction, helping reduce the risk of delayed diagnosis and infertility.

OVA1 is a blood-based multibiomarker test that assesses the likelihood that an ovarian/adnexal mass is malignant to help clinicians decide on specialist referral and surgical planning. By improving early detection and appropriate referral, it can help reduce the risk of delayed ovarian cancer diagnosis and worse outcomes.

DUPAN‑2 is a blood tumor marker used with imaging and other tests to help detect and monitor pancreatic and biliary tract cancers. By supporting earlier detection and surveillance of recurrence, it may help avoid progression to advanced disease and serious complications from those cancers.

This ALK gene test detects inherited or tumor-associated ALK alterations that signal elevated cancer risk or an actionable driver mutation. Knowing your ALK status can enable earlier diagnosis and access to targeted treatments for cancers such as non‑small‑cell lung cancer, anaplastic large‑cell lymphoma, and neuroblastoma, potentially improving outcomes.

This BRAF mutation test detects clinically significant changes in the BRAF gene (e.g., V600E) to confirm diagnosis and guide targeted treatment decisions for cancer. By identifying who will benefit from BRAF-targeted therapies, it can help avoid ineffective treatments and reduce the risk of cancer progression or recurrence—particularly in melanoma, colorectal, thyroid, lung cancers and hairy cell leukemia.

CYFRA 21‑1 is a blood test that measures cytokeratin‑19 fragments as a tumor marker to help detect and monitor certain cancers—most commonly non‑small‑cell (especially squamous) lung cancer—and to track treatment response and recurrence. By signaling changes in tumor activity earlier, it can help catch progression or relapse sooner, enabling timelier intervention and potentially better outcomes.

This EGFR mutation test detects actionable changes in the EGFR gene to guide targeted therapy decisions for patients with non‑small cell lung cancer. By identifying mutations that predict treatment response, it helps avoid ineffective treatments, reduce unnecessary side effects, and support earlier, more effective disease management.

A fast genetic test that detects HER2 (ERBB2) amplification or mutations in tumor tissue to identify whether you’re likely to benefit from HER2‑targeted therapies. Knowing your HER2 status helps guide more effective, personalized cancer treatment and may reduce the risk of ineffective therapy, disease progression, or recurrence.

Measures the kappa and lambda free immunoglobulin light chains to detect and monitor plasma‑cell disorders (e.g., multiple myeloma, light‑chain amyloidosis, MGUS). Early detection and monitoring can prompt treatment and reduce the risk of complications such as kidney damage, bone lesions, anemia and progressive organ dysfunction.

This Immunoglobulin test measures blood levels of key antibodies to assess your immune system’s strength and balance. It can help detect immune deficiencies, allergies or autoimmune activity and identify causes of recurrent or severe infections so you can get timely treatment.

Check your immunoglobulin (antibody) levels to see if your immune system is functioning properly. Detecting low or abnormal Ig levels can flag immune deficiencies, recurrent infection risk, or autoimmune/allergic tendencies so you can seek earlier care and reduce complications.

Detects abnormal monoclonal (M) proteins in blood and urine to screen for and monitor plasma‑cell disorders such as multiple myeloma, MGUS, and Waldenström. Early detection can enable timely treatment and help reduce the risk of kidney damage, bone lesions/fractures, anemia and other serious complications.

A Beta-2 microglobulin (B2M) test measures a small protein whose elevated levels indicate kidney damage, certain blood cancers (like multiple myeloma and lymphoma), immune activation, or transplant rejection. Identifying abnormalities early can prompt timely treatment and monitoring to reduce risk of kidney failure, delayed cancer diagnosis, or complications after transplant.

The ESR (erythrocyte sedimentation rate) test quickly detects inflammation in the body by measuring how fast red blood cells settle, helping identify infections, autoimmune conditions and other inflammatory disorders. Catching inflammation early can lead to faster treatment and reduce the risk of complications from untreated infections, arthritis flares, temporal arteritis and similar conditions.

A 5‑HIAA urine test measures the breakdown product of serotonin to screen for or monitor serotonin‑secreting carcinoid (neuroendocrine) tumors and related serotonin excess. Early detection can help prevent worsening carcinoid syndrome (flushing, diarrhea), tumor progression and complications such as carcinoid heart disease.

Chromogranin A (CgA) is a blood test that detects elevated levels of a neuroendocrine biomarker to help identify and monitor neuroendocrine tumors (e.g., carcinoid tumors, pheochromocytomas) and gauge treatment response. Early detection and monitoring can help prevent delayed diagnosis and complications from tumor growth or metastasis.

Chromogranin A (CgA) testing helps detect and monitor neuroendocrine tumors (such as carcinoid tumors, pheochromocytoma, and medullary thyroid cancer) by measuring a protein released by these cells. Early detection or rising CgA levels can prompt timely follow-up and treatment, reducing the risk of tumor growth, spread, and related complications.

Measures neuron‑specific enolase (NSE) in blood or CSF to help detect and monitor neuroendocrine tumors—most notably small‑cell lung cancer and neuroblastoma—as a tumor marker to guide treatment and follow‑up. It can also indicate neuronal injury after stroke, hypoxic brain damage or cardiac arrest, prompting earlier intervention to reduce long‑term neurologic complications.

Pancreastatin is a blood biomarker used to detect and monitor neuroendocrine tumors and pancreatic endocrine dysfunction. Testing can pick up abnormal hormone-producing tumors earlier, helping guide treatment and reduce the risk of tumor progression and hormone-related complications.

Detects the BRAF V600E genetic mutation found in cancers like melanoma, papillary thyroid cancer, colorectal cancer and hairy cell leukemia to guide targeted therapy and prognosis. Knowing your BRAF V600E status can help avoid ineffective treatments and enable earlier, personalized therapy that reduces the risk of cancer progression and metastasis.

Screening the KIT gene detects inherited or tumor-acquired KIT (c‑KIT) mutations that signal increased risk or presence of KIT-driven conditions. Identifying these variants enables earlier monitoring and targeted treatment decisions that can help catch or manage gastrointestinal stromal tumors, mast cell disorders, and some melanomas before they progress.

LDH (lactate dehydrogenase) measures an enzyme released with tissue damage and can flag liver disease, heart injury (including heart attack), hemolysis, muscle injury and some cancers. Catching abnormal LDH early helps prompt diagnosis and treatment, potentially avoiding severe complications.

This NRAS mutation test detects changes in the NRAS gene commonly found in melanoma, colorectal cancer and certain blood cancers. Knowing NRAS status can guide treatment selection and monitoring, helping clinicians choose more effective, targeted therapies sooner and avoid ineffective or delayed treatments.

A TERT promoter test detects mutations that turn on telomerase, flagging tumor presence and aggressiveness. It can help detect and monitor cancers (eg, glioma, melanoma, bladder, thyroid) earlier so treatment can begin sooner and reduce the risk of delayed diagnosis and worse outcomes.

A BCR‑ABL gene test detects the Philadelphia chromosome fusion to diagnose and monitor blood cancers (notably chronic myeloid leukemia and some acute leukemias). Early detection and ongoing monitoring guide targeted treatment decisions and help prevent disease progression, complications, and relapse.

The TP53 gene test screens for inherited mutations in the TP53 tumor‑suppressor gene that cause Li‑Fraumeni syndrome and greatly increase lifetime risk of multiple cancers, especially early‑onset breast cancer, sarcomas, brain tumors, adrenocortical carcinoma, and certain leukemias. Knowing your TP53 status can enable earlier, more intensive screening and preventive actions for you and at‑risk relatives, potentially improving early detection and risk management.

The AFP (alpha‑fetoprotein) blood test measures AFP levels to help screen for liver disease and certain cancers, and in pregnancy to detect potential fetal neural‑tube defects or chromosomal abnormalities. Early detection can prompt timely follow‑up and treatment, helping prevent progression to advanced liver cancer or other serious complications and ensuring earlier care for affected pregnancies.

The DCP test measures des‑gamma‑carboxy prothrombin (PIVKA‑II) in blood to assess risk and monitor for hepatocellular carcinoma (HCC) in patients with chronic liver disease. By detecting elevated DCP and tracking changes after treatment, it can help catch HCC earlier or identify recurrence—reducing the likelihood of advanced liver cancer and enabling earlier intervention.

The GP73 blood test measures Golgi protein 73, a liver biomarker used to detect liver disease and improve early identification of hepatocellular carcinoma (liver cancer). Early detection can enable prompt treatment and help reduce the risk of progression to cirrhosis, liver failure, or late-stage liver cancer.

The CAIX test measures Carbonic Anhydrase IX, a biomarker of tumor hypoxia used to detect and monitor certain cancers. By identifying elevated CAIX levels early, it can help guide treatment decisions and reduce the risk of delayed diagnosis and disease progression.

The LDH (lactate dehydrogenase) test measures an enzyme released when tissues are damaged, providing a quick signal of abnormal cell injury. Detecting elevated LDH early can prompt evaluation for liver disease, heart attack, hemolysis, muscle injury or certain cancers so you can get treatment sooner and reduce risk of complications.

This VEGF test measures vascular endothelial growth factor to detect abnormal blood‑vessel growth linked to cancers, diabetic retinopathy, age‑related macular degeneration, preeclampsia, and some cardiovascular conditions. Early identification of abnormal VEGF levels can prompt timely monitoring or treatment, potentially helping you avoid vision loss, tumor progression, pregnancy complications, and other serious outcomes.

The CA 72-4 test measures levels of the tumor-associated antigen CA 72-4 in blood to help detect and monitor gastrointestinal (especially gastric) and ovarian cancers. Regular testing can flag recurrence or treatment failure earlier, enabling timelier intervention and potentially better outcomes.

The ER/PR test checks whether breast tumor cells have estrogen and progesterone receptors to determine if hormone (endocrine) therapy is likely to work. Knowing receptor status helps avoid ineffective treatments and can reduce the risk of cancer progression and recurrence.

The ER/PR test checks whether breast tumor cells express estrogen and progesterone receptors so clinicians can choose the most effective, hormone-targeted therapies. Knowing ER/PR status can help avoid ineffective treatments and may reduce the risk of cancer progression or recurrence.

This MSI/dMMR test detects microsatellite instability or deficient DNA mismatch repair in tumors—markers of Lynch syndrome and MSI‑high cancers—so your care team can personalize treatment (including immunotherapy) and pursue family genetic assessment. By identifying risk early, it may prompt increased screening or preventive steps that help reduce the chance of advanced colorectal, endometrial and other Lynch‑associated cancers.

This P53 (TP53) gene test detects pathogenic changes in the TP53 tumor‑suppressor gene to identify inherited cancer risk (Li‑Fraumeni syndrome) or tumor-specific mutations that inform surveillance and treatment. Early detection of TP53 alterations can help you and your clinician take preventive steps and intensify monitoring to reduce the chance of late-stage breast cancer, sarcomas, brain tumors, adrenocortical carcinoma, leukemia and other TP53‑associated cancers.

This TP53 (p53) gene test identifies inherited mutations that markedly increase risk of multiple early-onset cancers. Knowing your status enables targeted surveillance and preventive steps to catch or reduce risk of cancers such as breast cancer, soft‑tissue and bone sarcomas, brain tumors, adrenocortical carcinoma, and certain leukemias.

CA 19‑9 is a blood test that measures a tumor marker most commonly used to detect and monitor pancreatic cancer and other biliary/gastrointestinal cancers. Regular testing can help identify recurrence or progression earlier, potentially avoiding delayed diagnosis and more advanced, harder-to-treat disease.

A CEA (carcinoembryonic antigen) blood test measures a tumor marker used to monitor treated colorectal (and some other) cancers and to detect early recurrence. Catching rising CEA levels sooner can prompt earlier treatment and help avoid progression to advanced-stage disease and its complications.

This test screens for harmful variants in PALB2 (sometimes called “BRCA3”) to identify an inherited increase in breast‑cancer risk and clarify family cancer susceptibility. Knowing your result lets you pursue earlier surveillance, risk‑reducing strategies, and personalized care to help prevent or detect breast cancer sooner; PALB2-related risk patterns are similar to BRCA2 and aren’t strongly linked to ovarian cancer.

CA 15-3 is a blood test that measures a tumor marker used to monitor breast cancer treatment and detect recurrence or progression. Regular CA 15-3 testing can alert you and your clinician to changes sooner, enabling earlier intervention that may help avoid more advanced disease and complications.

The CA 27‑29 blood test measures a tumor marker linked to breast cancer to monitor disease activity and treatment response. Detecting rising levels early can prompt timely intervention and may help reduce the risk of advanced or metastatic disease.

The Estrogen Receptor (ER) test checks whether tumor cells—most commonly in breast cancer—have receptors for estrogen, which determines if hormone (endocrine) therapies are likely to be effective. Knowing ER status helps guide targeted treatment choices, reducing the risk of cancer progression, recurrence, and unnecessary or ineffective therapies.

This HER2 test determines whether a tumor overexpresses the HER2 protein or has HER2 gene amplification to identify eligibility for HER2‑targeted therapies. Early, accurate HER2 detection helps avoid ineffective treatments and can reduce the risk of cancer progression and recurrence.

Detects whether a brain tumor (especially suspected oligodendroglioma) has the 1p/19q co‑deletion—a diagnostic and prognostic marker that predicts better response to chemo/radiation. Knowing this guides targeted treatment, helping avoid ineffective therapies or delays that can lead to tumor progression and worsening neurological outcomes.

Detects the EGFR vIII mutation — a tumor-specific EGFR alteration most commonly found in glioblastoma — to guide treatment selection and prognosis. Identifying EGFRvIII can help avoid ineffective therapies and delays in care, enabling targeted treatment decisions that may reduce tumor progression and recurrence.

Detects mutations in the IDH1 gene commonly found in gliomas, acute myeloid leukemia and intrahepatic cholangiocarcinoma, helping confirm diagnosis and identify eligibility for targeted IDH1 therapies. By enabling earlier, more precise treatment and monitoring, the test may reduce the risk of inappropriate therapy and help limit disease progression or relapse.

A fast genetic test that detects IDH2 mutations commonly found in acute myeloid leukemia and other myeloid cancers to guide targeted therapy decisions. Early identification of an IDH2 mutation enables personalized treatment and monitoring, which may reduce the risk of ineffective therapies, disease progression, and relapse.

The MGMT promoter methylation test detects whether the MGMT DNA-repair gene is epigenetically silenced in a tumor—information that predicts better response to alkylating chemotherapy (like temozolomide) in aggressive brain cancers such as glioblastoma. Knowing this status helps guide treatment choices so patients can avoid ineffective chemotherapy and its unnecessary side effects while pursuing more effective, personalized care.

The ALP (alkaline phosphatase) blood test measures an enzyme from the liver and bones to screen for liver dysfunction and bone disorders. Detecting abnormal ALP early can prompt timely diagnosis and treatment to help prevent problems such as bile duct obstruction, progressive liver disease, or bone metabolism disorders.

An ALP (alkaline phosphatase) blood test screens liver and bone health by detecting enzyme changes associated with liver disease, bile-duct obstruction and bone disorders. Early detection helps you address issues sooner and reduce the risk of progressing to serious liver or bone complications.

An LDH (lactate dehydrogenase) blood test detects elevated enzyme levels that signal tissue damage or inflammation, helping uncover problems like heart attack, liver disease, hemolytic anemia, muscle injury and certain cancers. Early detection lets you get prompt follow‑up and treatment, potentially preventing progression and complications.

This HPV DNA test screens for high-risk strains of human papillomavirus by detecting viral DNA, enabling early identification of infections that can lead to cervical precancers and cancer. Early detection can prompt timely follow-up and treatment to reduce the risk of cervical cancer and other HPV-related diseases.

The p16 INK4A test detects overexpression of the p16 protein—a reliable marker of high‑risk HPV–driven cellular changes—so doctors can identify and treat precancerous lesions early, reducing the risk of progression to cervical cancer.

The BTA (bladder tumor antigen) urine test is a rapid, non‑invasive immunoassay that detects bladder tumor–associated antigen to help screen for or monitor bladder cancer. By aiding earlier detection or surveillance of recurrence, it can help avoid delayed diagnosis and progression to more advanced bladder cancer when used alongside other clinical evaluations.

The NMP22 urine test detects elevated Nuclear Matrix Protein 22 levels linked to bladder cancer, offering a non‑invasive option for screening and monitoring. By helping spot cancer early or detect recurrence, it can prompt faster diagnosis and treatment, potentially avoiding advanced disease and more invasive therapies.

UroVysion FISH is a non‑invasive urine molecular test that detects chromosomal abnormalities associated with bladder (urothelial) cancer to screen for disease and monitor for recurrence. Detecting cancerous changes earlier enables prompt evaluation and treatment, helping prevent progression to more advanced bladder disease.

This ALK gene test detects ALK rearrangements and mutations to identify cancers (for example certain non‑small cell lung cancers, anaplastic large‑cell lymphomas and neuroblastomas) that may respond to ALK‑targeted therapies. Knowing your ALK status helps guide more effective, potentially less toxic treatment choices and avoid therapies unlikely to work.

This ALK gene test detects mutations or rearrangements in the ALK gene that are linked to cancers—most notably non‑small cell lung cancer, anaplastic large‑cell lymphoma and neuroblastoma. Knowing your ALK status enables earlier detection and access to targeted therapies, improving treatment options and reducing the risk of advanced disease.

The MYCN amplification test detects whether the MYCN oncogene is amplified in tumor tissue—a key marker used to identify high‑risk neuroblastoma. Knowing MYCN status helps clinicians choose timely, more aggressive treatment and closer monitoring to reduce the risk of disease progression and improve outcomes.

This MYCN amplification test detects whether a tumor carries extra copies of the MYCN oncogene, a critical prognostic marker used to identify high‑risk neuroblastoma and guide treatment intensity. Knowing MYCN status helps clinicians choose appropriate, timely therapy to reduce the risk of disease progression, relapse, and poor outcomes.

This WT1 gene test detects inherited or de novo mutations that increase risk of Wilms tumor and other WT1‑related kidney and gonadal disorders (e.g., Denys‑Drash, Frasier syndromes). Knowing your result enables targeted surveillance, earlier treatment, and informed family planning to reduce disease-related complications.